输注治疗在帕金森病中的应用。
Infusion Therapies in the Treatment of Parkinson's Disease.
机构信息
Department of Neurology, University Medical Center Groningen, University of Groningen, The Netherlands.
Parkinson's Foundation International Centre of Excellence, King's College Hospital, London, UK.
出版信息
J Parkinsons Dis. 2023;13(5):641-657. doi: 10.3233/JPD-225112.
Abstract
Oral levodopa is the gold-standard therapy for treating Parkinson's disease (PD) but after a few years of treatment the therapeutic window narrows, and patients often experience various treatment-related complications. Patients in this advanced PD stage may benefit from alternative therapy, such as continuous intrajejunal delivery of levodopa-carbidopa intestinal gel (LCIG; or carbidopa-levodopa enteral suspension), continuous intrajejunal delivery of levodopa-carbidopa-entacapone intestinal gel, or continuous subcutaneous apomorphine infusion. Consideration and initiation of infusion therapies in advanced PD are suggested before the onset of major disability. The present review summarizes clinical evidence for infusion therapy in advanced PD management, discusses available screening tools for advanced PD, and provides considerations around optimal use of infusion therapy.
摘要
口服左旋多巴是治疗帕金森病 (PD) 的金标准疗法，但经过几年的治疗后，治疗窗口变窄，患者经常出现各种与治疗相关的并发症。处于晚期 PD 阶段的患者可能受益于替代疗法，例如连续肠内给予左旋多巴-卡比多巴肠凝胶 (LCIG；或卡比多巴-左旋多巴肠混悬液)、连续肠内给予左旋多巴-卡比多巴-恩他卡朋肠凝胶，或持续皮下给予阿朴吗啡输注。建议在出现严重残疾之前考虑并开始对晚期 PD 进行输注治疗。本综述总结了晚期 PD 管理中输注治疗的临床证据，讨论了晚期 PD 的现有筛查工具，并就输注治疗的最佳使用提供了一些考虑。
相似文献
1
Infusion Therapies in the Treatment of Parkinson's Disease.
J Parkinsons Dis. 2023;13(5):641-657. doi: 10.3233/JPD-225112.
2
Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
Adv Ther. 2019 Sep;36(9):2233-2246. doi: 10.1007/s12325-019-01014-4. Epub 2019 Jul 5.
3
4
[Triple combination of levodopa, carbidopa and entacapone by intrajejunal pump in advanced Parkinson's disease].
Ideggyogy Sz. 2022 Nov 30;75(11-12):365-368. doi: 10.18071/isz.75.0365.
5
Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
Clin Pharmacokinet. 2015 Sep;54(9):975-84. doi: 10.1007/s40262-015-0265-3.
6
Initiation of Levodopa-Carbidopa Intestinal Gel Infusion Using Telemedicine (Video Communication System) Facilitates Efficient and Well-Accepted Home Titration in Patients with Advanced Parkinson's Disease.
J Parkinsons Dis. 2017;7(4):719-728. doi: 10.3233/JPD-161048.
7
The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
J Med Econ. 2017 Nov;20(11):1207-1215. doi: 10.1080/13696998.2017.1379411. Epub 2017 Sep 21.
8
Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience.
Eur J Neurol. 2014 Feb;21(2):312-8. doi: 10.1111/ene.12309. Epub 2013 Dec 7.
9
Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
Parkinsonism Relat Disord. 2016 Aug;29:17-23. doi: 10.1016/j.parkreldis.2016.06.002. Epub 2016 Jun 4.
10
Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.
AAPS J. 2013 Apr;15(2):316-23. doi: 10.1208/s12248-012-9439-1. Epub 2012 Dec 11.
引用本文的文献
1
Gamification-based tele-rehabilitation for physical therapy in patients with Parkinson's disease: A scoping review.
PLoS One. 2025 Aug 29;20(8):e0326705. doi: 10.1371/journal.pone.0326705. eCollection 2025.
2
Parkinson's Disease Database in the Middle East, North Africa, and South Asia Countries.
Int J Public Health. 2025 Jun 2;70:1608016. doi: 10.3389/ijph.2025.1608016. eCollection 2025.
3
Parkinson's Disease Multidisciplinary Complex Therapy (PD-MCT): appreciation of its current function for the treatment of people with Parkinson's disease in Germany and the needs of future development.
J Neural Transm (Vienna). 2025 Jun 12. doi: 10.1007/s00702-025-02963-7.
4
Efficacy and safety of continuous subcutaneous ND0612 Infusion compared to oral and alternative regimens in managing motor fluctuations in Parkinson's disease: a systematic review and meta-analysis.
Neurol Sci. 2025 Jun 2. doi: 10.1007/s10072-025-08257-w.
5
Levodopa-Entacapone-Carbidopa Intrajejunal Infusion in Advanced Parkinson's Disease - Interim Analysis of the ELEGANCE Study.
Mov Disord Clin Pract. 2025 Aug;12(8):1075-1085. doi: 10.1002/mdc3.70046. Epub 2025 Mar 25.
6
Use of the MNCD Classification to Monitor Clinical Stage and Response to Levodopa-Entacapone-Carbidopa Intestinal Gel Infusion in Advanced Parkinson's Disease.
Brain Sci. 2024 Dec 12;14(12):1244. doi: 10.3390/brainsci14121244.
7
Winding Back the Clock on Advanced Therapies: It's Time to Get Smart.
J Parkinsons Dis. 2024;14(7):1527-1530. doi: 10.3233/JPD-240193.
8
Myricetin mitigates motor disturbance and decreases neuronal ferroptosis in a rat model of Parkinson's disease.
Sci Rep. 2024 Jul 2;14(1):15107. doi: 10.1038/s41598-024-62910-6.
9
Current and novel infusion therapies for patients with Parkinson's disease.
J Neural Transm (Vienna). 2023 Nov;130(11):1349-1358. doi: 10.1007/s00702-023-02693-8. Epub 2023 Sep 6.
本文引用的文献
1
Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson's Disease: A Systematic Review and Bayesian Network Meta-analysis.
CNS Drugs. 2022 Dec;36(12):1269-1283. doi: 10.1007/s40263-022-00963-9. Epub 2022 Nov 21.
2
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
Lancet Neurol. 2022 Dec;21(12):1099-1109. doi: 10.1016/S1474-4422(22)00400-8.
3
Adverse effects of levodopa/carbidopa intrajejunal gel treatment: A single-center long-term follow-up study.
Acta Neurol Scand. 2022 Nov;146(5):537-544. doi: 10.1111/ane.13675. Epub 2022 Jul 28.
4
Long-term safety, discontinuation and mortality in an Italian cohort with advanced Parkinson's disease on levodopa/carbidopa intestinal gel infusion.
J Neurol. 2022 Oct;269(10):5606-5614. doi: 10.1007/s00415-022-11269-7. Epub 2022 Jul 25.
5
European Academy of Neurology/Movement Disorder Society - European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies.
Eur J Neurol. 2022 Sep;29(9):2580-2595. doi: 10.1111/ene.15386. Epub 2022 Jul 6.
6
Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease.
Neurology. 2022 Sep 5;99(10):e965-e976. doi: 10.1212/WNL.0000000000200804.
7
A Narrative Review of Specialist Parkinson's Nurses: Evolution, Evidence and Expectation.
Geriatrics (Basel). 2022 Apr 7;7(2):46. doi: 10.3390/geriatrics7020046.
8
Factors Affecting Adherence to Pharmacotherapy in Parkinson's Disease.
Ann Indian Acad Neurol. 2021 Nov-Dec;24(6):879-884. doi: 10.4103/aian.AIAN_143_21. Epub 2021 Aug 20.
9
Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum.
Parkinsonism Relat Disord. 2022 Apr;97:68-72. doi: 10.1016/j.parkreldis.2022.03.012. Epub 2022 Mar 22.
10
Does the 5-2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries.
BMC Neurol. 2022 Jan 24;22(1):35. doi: 10.1186/s12883-022-02560-1.
Zotero 插件